Every 8-K that bioAffinity Technologies, Inc. (BIAF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BIAF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIAF filings page.
bioAffinity Technologies reported it will present new research at CHEST 2025, the annual meeting of the American College of Chest Physicians. The company’s project manager for product development, Rossella Titone, PhD, will present the poster titled “The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests.”
The presentation is scheduled for October 22, 2025 at 10:20 a.m. at poster board #4324. The company attached its press release and the full poster as Exhibits 99.1 and 99.2, which are incorporated by reference.
bioAffinity Technologies (BIAF) reported a regulatory milestone. The company received a notification of allowance from the U.S. Patent and Trademark Office for a patent titled “Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning.” The patent covers a system and method for predicting the likelihood of lung cancer by analyzing patient sputum samples.
The company disclosed the news in a Form 8-K under Item 8.01 and attached a related press release as Exhibit 99.1. A notification of allowance indicates the USPTO intends to grant the patent following completion of administrative steps.
bioAffinity Technologies announced it has regained compliance with Nasdaq listing standards. A Nasdaq Hearings Panel found the company in compliance with Listing Rule 5550(a)(2) (the Minimum Bid Price Rule) and 5550(b)(1) (the Minimum Stockholders’ Equity Rule).
The company will be under a mandatory panel monitor for one year. If, during that period, it falls out of compliance with the Minimum Stockholders’ Equity Rule, it will not be granted additional time to regain compliance, though it may request a new hearing before any delisting. The company issued a press release on October 15, 2025, noting the compliance status.
bioAffinity Technologies entered into a securities purchase agreement with institutional investors for a registered direct offering of 720,000 shares of common stock. The transaction closed on October 9, 2025, providing the company with approximately $1.8 million in gross proceeds before placement fees and expenses.
WallachBeth Capital, LLC acted as exclusive placement agent and will receive a cash fee of 8.0% of the gross proceeds plus up to $75,000 of expense reimbursement. The company agreed that, until November 14, 2025, it will not issue most additional equity, and it will not enter into variable rate transactions for six months after the closing date, with the restriction on at-the-market offerings and equity lines ending on November 14, 2025. Officers and directors also signed 60‑day lock-up agreements limiting sales of company securities.
bioAffinity Technologies, Inc. reported that sales of its CyPath® Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025. The company disclosed this business update through a press release, which is furnished as an exhibit to this report.
The filing does not include detailed financial figures, but highlights growing adoption of the CyPath® Lung test as a notable operating milestone for the period.
bioAffinity Technologies, Inc. filed a Current Report on Form 8-K disclosing a corporate action: the company announced a Reverse Stock Split and furnished a related press release dated September 17, 2025. The filing also includes a Certificate of Amendment to the Certificate of Incorporation as Exhibit 3.1, and the press release is furnished as Exhibit 99.1. The 8-K indicates these documents are part of the company's report of a material event but does not provide the split ratio or detail any effects on shares outstanding, shareholder approvals, or listing status within the disclosed text.